<DOC>
	<DOCNO>NCT02714062</DOCNO>
	<brief_summary>The primary objective study describe pharmacokinetic profile VI-0521 obese adolescent .</brief_summary>
	<brief_title>A Pharmacokinetic Study Comparing VI-0521 With Placebo Obese Adolescents</brief_title>
	<detailed_description />
	<mesh_term>Obesity</mesh_term>
	<mesh_term>Pediatric Obesity</mesh_term>
	<criteria>Provide write informed consent Provide write assent ( study subject ) ; Adolescent ≥12 &lt; 18 year age ; Have BMI ≥ 95th percentile BMI age gender ; Female subject must use adequate contraception ; Willing able comply study requirement Condition disease interfere metabolism ; Any medical treatment insulin ; Hyperthyroidism , clinically significant hypothyroidism ; Any history bipolar disorder psychosis , major depressive disorder , history suicidal behavior ideation , use antidepressant medication ; Use chronic systemic glucocorticoid steroid therapy ; History eat disorder ; Any history laxative abuse ; Prior bariatric surgery ; Any history nephrolithiasis ; Any history epilepsy , treatment antiseizure medication ; Positive urine drug screen ; Current smoker smoking cessation within previous 3 month screen ; Obesity know genetic endocrine origin ; Treatment overthecounter prescription weight loss drug , attentiondeficit/hyperactivity disorder ( ADHD ) ; Allergy hypersensitivity phentermine topiramate history anaphylaxis drug ; Use investigational medication device indication participation clinical study within 30 day prior screen ; Any medical surgical condition would impair ability subject complete study , compromise quality study data , pose unacceptable risk safety subject .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Adolescent Obesity</keyword>
	<keyword>Childhood Obesity</keyword>
	<keyword>Qsymia</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>VI-0521</keyword>
</DOC>